Pacific Shuanglin Bio-pharmacy Past Earnings Performance
Past criteria checks 4/6
Pacific Shuanglin Bio-pharmacy has been growing earnings at an average annual rate of 35.9%, while the Biotechs industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 24.3% per year. Pacific Shuanglin Bio-pharmacy's return on equity is 9%, and it has net margins of 27.1%.
Key information
35.9%
Earnings growth rate
27.7%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 24.3% |
| Return on equity | 9.0% |
| Net Margin | 27.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pacific Shuanglin Bio-pharmacy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,504 | 678 | 468 | 86 |
| 31 Dec 23 | 2,329 | 612 | 464 | 80 |
| 30 Sep 23 | 2,287 | 564 | 547 | 85 |
| 30 Jun 23 | 2,123 | 509 | 553 | 79 |
| 31 Mar 23 | 2,166 | 538 | 536 | 75 |
| 01 Jan 23 | 2,405 | 587 | 575 | 75 |
| 30 Sep 22 | 2,123 | 437 | 473 | 56 |
| 30 Jun 22 | 2,172 | 436 | 474 | 43 |
| 31 Mar 22 | 2,187 | 440 | 475 | 43 |
| 01 Jan 22 | 1,972 | 391 | 427 | 36 |
| 30 Sep 21 | 1,730 | 386 | 394 | 28 |
| 30 Jun 21 | 1,413 | 299 | 329 | 24 |
| 31 Mar 21 | 1,124 | 217 | 282 | 16 |
| 01 Jan 21 | 1,050 | 186 | 272 | 11 |
| 30 Sep 20 | 937 | 137 | 260 | 11 |
| 30 Jun 20 | 941 | 146 | 265 | 11 |
| 31 Mar 20 | 949 | 161 | 263 | 12 |
| 01 Jan 20 | 916 | 160 | 264 | 15 |
| 30 Sep 19 | 867 | 127 | 292 | 23 |
| 30 Jun 19 | 835 | 91 | 299 | 25 |
| 31 Mar 19 | 819 | 76 | 303 | 29 |
| 01 Jan 19 | 860 | 80 | 310 | 29 |
| 30 Sep 18 | 805 | 60 | 275 | 31 |
| 30 Jun 18 | 791 | 44 | 254 | 41 |
| 31 Mar 18 | 771 | 30 | 251 | 34 |
| 31 Dec 17 | 685 | 22 | 244 | 29 |
| 30 Sep 17 | 652 | 34 | 267 | 15 |
| 30 Jun 17 | 600 | 52 | 265 | 0 |
| 31 Mar 17 | 530 | 52 | 240 | 0 |
| 31 Dec 16 | 561 | 50 | 230 | 0 |
| 30 Sep 16 | 545 | 68 | 190 | 0 |
| 30 Jun 16 | 527 | 66 | 172 | 0 |
| 31 Mar 16 | 554 | 81 | 168 | 0 |
| 31 Dec 15 | 500 | 78 | 159 | 0 |
| 30 Sep 15 | 568 | 70 | 149 | 0 |
| 30 Jun 15 | 587 | 75 | 145 | 0 |
| 31 Mar 15 | 513 | 32 | 136 | 0 |
| 31 Dec 14 | 489 | 123 | 133 | 0 |
| 30 Sep 14 | 403 | 105 | 138 | 0 |
| 30 Jun 14 | 393 | 118 | 137 | 0 |
| 31 Mar 14 | 444 | 149 | 147 | 0 |
| 31 Dec 13 | 478 | 70 | 148 | 0 |
| 30 Sep 13 | 496 | 70 | 101 | 0 |
| 30 Jun 13 | 474 | 52 | 118 | 0 |
Quality Earnings: 000403 has high quality earnings.
Growing Profit Margin: 000403's current net profit margins (27.1%) are higher than last year (24.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000403's earnings have grown significantly by 35.9% per year over the past 5 years.
Accelerating Growth: 000403's earnings growth over the past year (26%) is below its 5-year average (35.9% per year).
Earnings vs Industry: 000403 earnings growth over the past year (26%) exceeded the Biotechs industry -3.9%.
Return on Equity
High ROE: 000403's Return on Equity (9%) is considered low.